FDA approves Mylan's biosimilar for breast, stomach cancer: 4 things to know

The FDA approved Mylan's biosimilar cancer drug Ogivri Dec. 1.

Here are four things to know.

1. Ogivri is a biosimilar version of Genentech's cancer drug Herceptin.

2. The drug is intended to treat patients with breast or metastatic stomach cancer.

3. Ogivri is the second biosimilar approved for cancer, and the first approved to treat stomach and breast cancer.

4. Both Ogivri and Herceptin contain a boxed warning over an increased risk of heart disease, infusion reactions, lung damage and harm to fetuses.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars